Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director · Chief Executive Officer | September 19, 2025 | December 22, 2025 |
| Canton Strategic Holdings, Inc.THAR · Entity 6394 | Director | August 09, 2024 | August 12, 2024 |
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director · Chief Executive Officer | August 08, 2025 | September 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,700,000 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 1,700,000 · Balance 1,700,000 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Canton Strategic Holdings, Inc.
Report date August 09, 2024 · Filed August 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2034-08-09 | Direct | 27,353 |
Reported balance
After 2024-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-09 · Grant · Acquired 2,353 · Balance 27,353 F1: On August 9, 2024, the Reporting Person was granted options ("Options") to purchase up to 2,353 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 9, 2024, the Reporting Person was granted options ("Options") to purchase up to 2,353 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant.
Citius Pharmaceuticals, Inc.
Report date August 08, 2025 · Filed September 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $28.75 · Expires 2025-08-14 | Direct | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-08 · Disposition to issuer · Disposed 125,490 · Balance 0 F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $28.75 · Expires 2026-08-14 | Direct | 125,490 |
Reported balance
After 2025-08-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-08 · Grant · Acquired 125,490 · Balance 125,490 F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2025-09-27 | Direct | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-08 · Disposition to issuer · Disposed 89,388 · Balance 0 F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2026-09-27 | Direct | 89,388 |
Reported balance
After 2025-08-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-08-08 · Grant · Acquired 89,388 · Balance 89,388 F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. |
| Common StockSEC Table I · non-derivative | Direct | 410,214 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 410,214 |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-11-07 | Direct | 24,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 24,000 F3: The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $17.50 · Expires 2033-10-10 | Direct | 22,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 22,000 F4: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $31.25 · Expires 2032-10-04 | Direct | 22,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 22,000 F5: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $51.00 · Expires 2031-10-11 | Direct | 26,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 26,000 F6: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $50.00 · Expires 2031-07-22 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 12,000 F6: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2030-10-06 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 8,000 F6: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2029-10-08 | Direct | 7,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 7,000 F6: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $40.50 · Expires 2028-09-04 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 6,000 F6: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $86.25 · Expires 2027-09-13 | Direct | 1,600 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 1,600 F6: The options are vested in full and exercisable immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
F3: The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F4: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F5: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F6: The options are vested in full and exercisable immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 1,700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090614 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 1,700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116675 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 1,700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124533 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700,000 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| August 08, 2025 Filed Sep 23, 2025 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 89,388 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001213900-25-090602 · ownership.xml · derivative · entry 5 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,388 Underlying: Common Stock · 89,388 shares Expires 2026-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Sep 23, 2025 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 89,388 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001213900-25-090602 · ownership.xml · derivative · entry 4 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,388 shares Expires 2025-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Sep 23, 2025 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 125,490 | Not disclosed Strike: $28.75 | Not disclosed |
DisclosureSEC source: 0001213900-25-090602 · ownership.xml · derivative · entry 3 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,490 Underlying: Common Stock · 125,490 shares Expires 2026-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Sep 23, 2025 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 125,490 | Not disclosed Strike: $28.75 | Not disclosed |
DisclosureSEC source: 0001213900-25-090602 · ownership.xml · derivative · entry 2 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,490 shares Expires 2025-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:05 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109293 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 17:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 600,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096892 · ownership.xml · derivative · entry 2 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 17:26 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 2,234,700 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-24-082812 · ownership.xml · derivative · entry 5 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,234,700 Underlying: Common Stock · 2,234,700 shares Expires 2025-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 17:26 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 2,234,700 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-24-082812 · ownership.xml · derivative · entry 4 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,234,700 shares Expires 2024-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 14, 2024 Filed Sep 27, 2024 17:26 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 3,137,255 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-24-082812 · ownership.xml · derivative · entry 3 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,137,255 Underlying: Common Stock · 3,137,255 shares Expires 2025-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 14, 2024 Filed Sep 27, 2024 17:26 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 3,137,255 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-24-082812 · ownership.xml · derivative · entry 2 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,137,255 shares Expires 2024-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:27 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 1,233,333 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-069248 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233,333 Underlying: Common Stock · 1,233,333 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 3,700,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074519 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700,000 Underlying: Common Stock · 3,700,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 21:18 UTC | Canton Strategic Holdings, Inc. THAR · Entity 6394 | GrantOptions (right to buy) · Derivative | 2,353 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001493152-24-031367 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,353 Underlying: Common stock · 2,353 shares Expires 2034-08-09 F1 · derivative.exercise_date: On August 9, 2024, the Reporting Person was granted options ("Options") to purchase up to 2,353 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 1,165,048 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-24-030811 · ownership.xml · derivative · entry 3 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,048 Underlying: Common Stock · 1,165,048 shares Expires 2025-04-05 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 1,165,048 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-24-030811 · ownership.xml · derivative · entry 2 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,165,048 shares Expires 2024-04-05 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. Read SEC document |
| November 07, 2023 Filed Nov 10, 2023 00:48 UTC | Canton Strategic Holdings, Inc. THAR · Entity 6394 | GrantOptions (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001493152-23-040165 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2033-11-07 F1 · derivative.exercise_date: On November 7, 2023, the Reporting Person was granted options ("Options") to purchase up to 25,000 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 16:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOption to Purchase Common Stock · Derivative | 550,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001013762-23-003528 · ownership.xml · derivative · entry 13 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2033-10-10 F10 · security: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F10 · derivative.exercise_date: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOption to Purchase Common Stock · Derivative | 550,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001213900-22-062481 · ownership.xml · derivative · entry 16 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-10-04 F9 · security: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F9 · derivative.exercise_date: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:15 UTC | Canton Strategic Holdings, Inc. HILS · Entity 6394 | GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-22-007541 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2032-03-21 F1 · derivative.exercise_date: On March 21, 2022, the Reporting Person was granted options ("Options") to purchase up to 50,000 shares of the Registrant's common stock pursuant to the Registrant's 2019 Stock Incentive Plan. The Options vest in 12 equal monthly installments with the first installment vesting on the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:09 UTC | Canton Strategic Holdings, Inc. HILS · Entity 6394 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $3.20 | $300,000.00 |
DisclosureSEC source: 0001493152-22-001473 · ownership.xml · derivative · entry 3 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 98,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On December 22, 2020, the Registrant issued the Reporting Person a $300,000 note which matures on the earlier of (i) December 31, 2023 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. Pursuant to the terms of the note, because the Registrant's initial public offering qualified as a Next Equity Financing, the note automatically converted into shares of the Registrant's common stock. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents. F1 · derivative.expiration_date: On December 22, 2020, the Registrant issued the Reporting Person a $300,000 note which matures on the earlier of (i) December 31, 2023 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. Pursuant to the terms of the note, because the Registrant's initial public offering qualified as a Next Equity Financing, the note automatically converted into shares of the Registrant's common stock. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:09 UTC | Canton Strategic Holdings, Inc. HILS · Entity 6394 | PurchaseCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001493152-22-001473 · ownership.xml · nonDerivative · entry 2 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,733 Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:09 UTC | Canton Strategic Holdings, Inc. HILS · Entity 6394 | ConversionCommon Stock | 98,733 | $3.20 | $315,945.60 |
DisclosureSEC source: 0001493152-22-001473 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 17:25 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOption to Purchase Common Stock · Derivative | 650,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-21-052677 · ownership.xml · derivative · entry 15 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2031-10-11 F8 · security: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F8 · derivative.exercise_date: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 17:02 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038695 · ownership.xml · derivative · entry 14 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-07-22 F7 · security: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F7 · derivative.exercise_date: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| October 06, 2020 Filed Oct 9, 2020 16:07 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001213900-20-030793 · ownership.xml · derivative · entry 18 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-10-06 F7 · security: The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F7 · derivative.exercise_date: The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 16:14 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 175,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-19-020122 · ownership.xml · derivative · entry 21 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-10-08 F6 · derivative.exercise_date: The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| September 27, 2019 Filed Sep 27, 2019 16:16 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseWarrant to Purchase Common Stock · Derivative | 2,234,700 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-19-019180 · ownership.xml · derivative · entry 20 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,234,700 Underlying: Common Stock · 2,234,700 shares Expires 2024-09-27 F2 · security: The warrant is fully vested and exercisable immediately. F4 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F2 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| September 27, 2019 Filed Sep 27, 2019 16:16 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 2,234,700 | $0.90 | $2,000,279.97 |
DisclosureSEC source: 0001213900-19-019180 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,255,343 Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseWarrant to Purchase Common Stock · Derivative | 1,165,048 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-19-005844 · ownership.xml · derivative · entry 19 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,048 Underlying: Common Stock · 1,165,048 shares Expires 2021-04-05 F2 · security: The warrant is fully vested and exercisable immediately. F4 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F2 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 1,165,048 | $1.55 | $1,799,999.16 |
DisclosureSEC source: 0001213900-19-005844 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020,643 Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:14 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 150,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-18-012199 · ownership.xml · derivative · entry 18 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-09-04 F5 · security: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date. F5 · derivative.exercise_date: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 17:07 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 3,137,255 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-18-011213 · ownership.xml · derivative · entry 17 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,137,255 Underlying: Common Stock · 3,137,255 shares Expires 2023-08-14 F2 · security: The warrant is fully vested and exercisable immediately. F4 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F2 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 17:07 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 3,137,255 | $1.28 | $4,000,000.13 |
DisclosureSEC source: 0001213900-18-011213 · ownership.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,855,595 Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 15:56 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseWarrant to Purchase Common Stock · Derivative | 167,504 | Not disclosed Strike: $2.86 | Not disclosed |
DisclosureSEC source: 0001213900-18-003856 · f4032918mazur_citiuspharma.xml · derivative · entry 16 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,504 Underlying: Common Stock · 167,504 shares Expires 2023-09-29 F2 · security: The warrant is fully vested and exercisable immediately. F6 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F2 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 15:56 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 167,504 | $2.99 | $499,999.44 |
DisclosureSEC source: 0001213900-18-003856 · f4032918mazur_citiuspharma.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718,340 Read SEC document |
| December 19, 2017 Filed Jan 8, 2018 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 213,106 | $4.69 | $999,467.14 |
DisclosureSEC source: 0001213900-18-000250 · f4121917mazur_citiuspharma.xml · nonDerivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,550,836 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.